Anticancer agent 284

• Description :

  Anticancer agent 284 exhibits cytotoxicity against osteosarcoma cell line (Hos), non-small cell lung cancer cell line (A549), and colon cancer cell line (HCT-116) . Anticancer agent 284 can impact the pRIPK3 kinase concentration in the A549 (2.97 pg/mL) . Anticancer agent 284 can be used for the study of cancer[1].

• UNSPSC :

  12352005

• Target :

  RIP kinase

• Related Pathways :

  Apoptosis

• Field of Research :

  Cancer

• Smiles :

  CC1=CC=C(C=C1)S(=O)(N/N=C(C2=CC=C(C=C2)N/C=C3C(N(N=C/3C)C4=CC=CC=C4)=O)\C)=O

• Molecular Formula :

  C26H25N5O3S

• Molecular Weight :

  487.57

• References & Citations :

  [1]Ahmed AA, et al. Multi-step organic synthesis, cytotoxicity, and molecular docking of new N-phenylpyrazolones incorporated with N-benzylthiazole or N-benzyl-4-thiazolone fragments. Sci Rep. 2025 Sep 29;15 (1) :33340.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported